Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 7, 2015; 21(13): 3970-3977
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3970
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3970
Table 1 Baseline characteristics of all 132 patients n (%)
Baseline characteristics | Value |
Age, yr | |
> 65 | 20 (15.2) |
≤ 65 | 112 (84.8) |
Gender | |
Male | 121 (91.7) |
Female | 11 (8.3) |
CLIP score | |
0 or 1 | 0 (0) |
2 | 38 (28.8) |
3 | 47 (35.6) |
4 | 47 (35.6) |
BCLC | |
A | 0 (0) |
B | 53 (40.2) |
C | 79 (59.8) |
D | 0 (0) |
ECOG Performance Status | |
0 | 87 (65.9) |
1 | 35 (26.5) |
2 | 10 (7.6) |
AFP, ng/mL (mean ± SD) | 15038.8 ± 22661.5 |
< 20 | 27 (20.5) |
20-400 | 23 (17.4) |
> 400 | 82 (62.1) |
Tumor nodules | |
Solitary | 110 (83.3) |
Multiple | 22 (16.7) |
Vascular invasion | |
With | 75 (56.8) |
Without | 57 (43.2) |
Extrahepatic metastasis | |
With | 40 (30.3) |
Without | 92 (69.7) |
Child-Pugh stage | |
A | 129 (97.7) |
B | 3 (2.3) |
HBV infection1 | |
Yes | 129 (97.7) |
No | 3 (2.3) |
HBV DNA level > 104 copies/mL | 50 (37.9) |
HCV antibody | |
Positive | 0 |
Negative | 132 (100) |
Cirrhosis | |
With | 124 (93.9) |
Without | 8 (6.1) |
Table 2 Univariate and multivariate analysis of predictors of tumor progression of all 132 patients
Characteristic | Univariate | Multivariate | HR | 95%CI |
Age ( ≤ 65 yr >) | 0.84 | |||
Gender | 0.88 | |||
Clip score | 0.05 | |||
BCLC (B, C) | 0.02 | |||
ECOG (0, 1, 2) | 0.59 | |||
Cirrhosis | 0.79 | |||
Solitary or multiple nodules | 0.50 | |||
Vascular invasion | 0.01 | 0.30 | 0.75 | 0.44-1.29 |
Extrahepatic spread | 0.04 | 0.26 | 0.73 | 0.42-1.27 |
AFP-pre | 0.02 | |||
< 20 ng/mL | 0.05 | |||
20-400 ng/mL | 0.04 | 0.55 | 0.30-0.99 | |
> 400 ng/mL | 0.50 | 1.23 | 0.67-2.28 | |
HBV DNA > 104 copies/mL | 0.66 | |||
Gelatin-sponge application | 0.26 |
Table 3 Univariate and multivariate analysis of predictors of survival of all 132 patients
Characteristic | Univariate | Multivariate | HR | 95%CI |
Age ( ≤ 65 yr >) | 0.53 | |||
Gender | 0.46 | |||
Clip score | 0.29 | |||
BCLC (B, C) | 0.03 | |||
ECOG (0, 1, 2) | 0.57 | |||
Cirrhosis | 0.73 | |||
Solitary or multiple nodules | 0.74 | |||
Vascular invasion | 0.00 | 0.00 | 2.36 | 1.41-2.94 |
Extrahepatic spread | 0.04 | 0.34 | 1.27 | 0.78-2.10 |
AFP-pre | 0.02 | |||
< 20 ng/mL | 0.09 | |||
20-400 ng/mL | 0.19 | 0.71 | 0.43-1.20 | |
> 400 ng/mL | 0.22 | 1.41 | 0.81-2.49 | |
HBV DNA > 104 copies/mL | 0.21 | |||
Gelatin-sponge application | 0.47 |
Table 4 Tumor responses after treatment of 103 patients
Parameter | n (%) |
16-wk disease-control rate | 50% |
Best response | |
Complete response | 0 (0.0) |
Partial response | 22 (21.4) |
Stable disease | 58 (56.3) |
Progressive disease | 23 (22.3) |
AFP response rate (decrease > 25%) | 39 (37.9) |
No AFP response rate | 64 (62.1) |
Change < 25% | 39 (37.9) |
Increase > 25% | 25 (24.3) |
- Citation: Li JH, Xie XY, Zhang L, Le F, Ge NL, Li LX, Gan YH, Chen Y, Zhang JB, Xue TC, Chen RX, Xia JL, Zhang BH, Ye SL, Wang YH, Ren ZG. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World J Gastroenterol 2015; 21(13): 3970-3977
- URL: https://www.wjgnet.com/1007-9327/full/v21/i13/3970.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i13.3970